hydroxychloroquine has been researched along with Experimental Lung Inflammation in 9 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Experimental Lung Inflammation: Inflammation of any part, segment or lobe, of the lung parenchyma.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The novel coronavirus disease 2019 (COVID-19) has a broad spectrum of clinical manifestations, the most common serious clinical manifestation of the coronavirus infection being pneumonia." | 5.72 | EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA. ( Berber, N; Cagasar, O; Delen, LA; Derya, S; Gok, A; Gok, Z; Kasapoglu, US; Tetik, B, 2022) |
| "The main aim of this study was to examine the differences between triple therapy (T: SSZ and HCQ added to MTX) and etanercept (E) added to MTX with regard to the infectious and gastrointestinal (GI) adverse events (AEs) reported in The Rheumatoid Arthritis Comparison of Active Therapies Trial." | 2.84 | Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events. ( Brophy, MT; Chang, BH; Hannagan, K; O'Dell, JR; Quach, LT; Soe Thwin, S, 2017) |
| "The novel coronavirus disease 2019 (COVID-19) has a broad spectrum of clinical manifestations, the most common serious clinical manifestation of the coronavirus infection being pneumonia." | 1.72 | EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA. ( Berber, N; Cagasar, O; Delen, LA; Derya, S; Gok, A; Gok, Z; Kasapoglu, US; Tetik, B, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Delen, LA | 1 |
| Gok, A | 1 |
| Kasapoglu, US | 1 |
| Cagasar, O | 1 |
| Gok, Z | 1 |
| Berber, N | 1 |
| Derya, S | 1 |
| Tetik, B | 1 |
| Bekci, T | 1 |
| Hong, SI | 1 |
| Ryu, BH | 1 |
| Chong, YP | 1 |
| Lee, S | 1 |
| Kim, S | 1 |
| Kim, HC | 1 |
| Hong, KW | 1 |
| Bae, IG | 1 |
| Cho, OH | 1 |
| Li, Q | 1 |
| Cui, C | 1 |
| Xu, F | 1 |
| Zhao, J | 1 |
| Li, N | 1 |
| Li, H | 2 |
| Wang, T | 1 |
| Zhang, H | 1 |
| Liu, N | 1 |
| Wei, Y | 1 |
| Niu, X | 1 |
| Xu, Y | 1 |
| Dong, J | 1 |
| Yao, X | 1 |
| Wang, X | 1 |
| Chen, Y | 1 |
| Song, C | 1 |
| Qiao, J | 1 |
| Liu, D | 1 |
| Shen, N | 1 |
| Best, JH | 1 |
| Kong, AM | 1 |
| Kaplan-Lewis, E | 1 |
| Brawley, OW | 1 |
| Baden, R | 1 |
| Zazzali, JL | 1 |
| Miller, KS | 1 |
| Loveless, J | 1 |
| Jariwala-Parikh, K | 1 |
| Mohan, SV | 1 |
| Lazovic, B | 1 |
| Zlatkovic-Svenda, M | 1 |
| Jasarovic, D | 1 |
| Stevanovic, D | 1 |
| Shi, W | 1 |
| Duan, M | 1 |
| Jie, L | 1 |
| Sun, W | 1 |
| Quach, LT | 1 |
| Chang, BH | 1 |
| Brophy, MT | 1 |
| Soe Thwin, S | 1 |
| Hannagan, K | 1 |
| O'Dell, JR | 1 |
| Knight, AK | 1 |
| Cunningham-Rundles, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy[NCT00405275] | 353 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Average difference between 48-week and Baseline DAS28.~The Disease Activity Score for 28 Joints (DAS28) is a well-validated composite outcome measure ranging from 2-10 (higher scores indicating more disease) that incorporates a tender and swollen joint count of 28 joints, a laboratory measure of systemic inflammation (ESR) and a patient-reported general assessment of health on a visual analog scale (ranging from 0-10cm) all into one measure.~Low disease activity is defined as DAS28 ≤ 3.2 units." (NCT00405275)
Timeframe: 48 weeks after baseline assessment
| Intervention | units on a scale (Mean) |
|---|---|
| Triple | -2.12 |
| Etanercept | -2.29 |
1 review available for hydroxychloroquine and Experimental Lung Inflammation
| Article | Year |
|---|---|
Inflammatory and autoimmune complications of common variable immune deficiency.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
1 trial available for hydroxychloroquine and Experimental Lung Inflammation
| Article | Year |
|---|---|
Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
Topics: Abscess; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etaner | 2017 |
7 other studies available for hydroxychloroquine and Experimental Lung Inflammation
| Article | Year |
|---|---|
EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA.
Topics: Aged; Amides; Antimalarials; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Disease Progressio | 2022 |
"Reversed halo sign" on 3D CT in COVID-19.
Topics: Adult; Antimalarials; Antiviral Agents; Betacoronavirus; Body Fluids; Coronavirus Infections; COVID- | 2020 |
Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.
Topics: Adjuvants, Immunologic; Adult; Aged; Antimalarials; Antiviral Agents; Betacoronavirus; Coronavirus I | 2020 |
Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pneumonia; SARS- | 2021 |
Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-Inflammatory Agen | 2021 |
Systemic Lupus Erythematosus Presenting as Acute Lupus Pneumonitis.
Topics: Acute Disease; Aged; Chest Pain; Diagnosis, Differential; Dyspnea; Emergencies; Female; Fever; Human | 2018 |
A successful treatment of severe systemic lupus erythematosus caused by occult pulmonary infection-associated with hemophagocytic syndrome: A case report.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Blood Cell Count; Bone Marrow Examination; Cilas | 2018 |